Novvae Logo

Rising to Meet Consumer Demand

Developing OTC products with patented metered-dose platforms for transdermal and intranasal drug delivery

Novvae Pharmaceuticals Inc. is being positioned to meet unmet needs in the antiviral market.

The global topical and intranasal drug delivery markets are on the rise and our products are ready to meet them. With the increase in demand for self-administered and home care, consumers are seeking reliable over-the-counter drugs to manage healthier lifestyles.

Optimizing Intranasal Drug Delivery

in the prophylactic prevention of influenza, covid, and many negatively charged viruses, including the rhino virus (common cold).

Global Intranasal Drug Delivery

The intranasal drug delivery market size is projected to reach $92.6 billion by 2030, growing at a CAGR of 6.6% from 2022 to 2030.1

Reasons for growth

  • Increase in consumer desire to stop the spread of viral infections

  • Increase in demand for self-administered treatments
Global Intranasal drug delivery market size

Novvae is Positioned to Transform the

Non-Prescription Intranasal Antiviral Market with…


AnQlar is a chitosan derivative and a natural antimicrobial delivered as a meter-dosed intranasal nanoparticle dispersion. Its positively charged mucoadhesive attributes create a 24-hour prophylactic barrier against Covid, flu, and the common cold. Its antiviral barrier activity against Covid has been demonstrated in three preclinical studies.

Antiviral global market size is $13.16 billion USD
Product benefits

Potential Benefits

  • Targeted delivery and viral barrier activity in the nasal mucosa where viruses start
  • May be used as a frontline defense against disease spread in close settings
  • May be a viral barrier against influenza and Covid for 24 hours
  • An adjuvant to barrier-based personal protective equipment (PPE) to help mitigate the risks of poorly fitting equipment and over-used PPE with partially compromised barrier layers
  • May be used by vaccinated and unvaccinated individuals to prevent viral spread
  • Demonstrated no viral brain load when exposed to SARS-CoV-2 in preclinical studies
Product benefits

Positioning our pipeline to meet unmet needs in

Multi-billion dollar consumer markets

Global OTC Topical Drugs Market

The global topical drug delivery market is projected to reach $317.8 billion in revenue by 2027, growing at a CAGR of 8.9% from 2022 to 2027.2

Reasons for growth

  • Increase in demand for self-administered treatments
  • Increase in aging population
Global Topical drug delivery market size

Positioned to Transform the Multibillion-Dollar Non-Prescription

Topical and Transdermal Drug Delivery Market with…

Growth opportunities
Growth opportunities

Growth Opportunity (Transdermal)

Our Metered Dose Spray System (MDSS) may be used to deliver OTC products like the oxybutynin transdermal patch for overactive bladder, and the nicotine patch to help stop smoking.

Benefits of MDSS Oxybutynin and Nicotine compared to their current patch formulations

  • No concern with transdermal adhesion
  • Satisfactory skin permeation
  • Reliable and reproducible blood levels
  • Avoids skin irritation associated with their occlusive backing.
  • More aesthetically pleasing.
  • Improved patient compliance could result in better therapeutic outcomes.
  • No environmental concerns
Product benefits